Direct-acting antiviral treatment of acute hepatitis C virus infections

Suresh Misra, Douglas T. Dieterich, Behnam Saberi, Tatyana Kushner

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Introduction: Hepatitis C contributes to significant morbidity and mortality worldwide. AHCV is defined as documented infection within 6 months of exposure. Treating acute hepatitis C virus (AHCV) with direct-acting antiviral agents in persons who inject drugs, HIV-positive men who have sex with men, and patients who acquire HCV nosocomially can contribute to the elimination of disease globally, preclude the morbidity and mortality of chronic disease, and prevent further transmission. Areas covered: In this review, we describe the epidemiology of AHCV, its natural history, the considerations involved in the decision of whether to treat AHCV, and the most current DAA therapy guidelines. PubMed was queried using key words and bibliographies were evaluated for relevant articles. Expert commentary: Despite the obvious benefits of AHCV treatment, clinical management is limited by the ability to identify asymptomatic cases and the absence of fully supported guidelines. However, clinical research is advancing and identifying specific regimens, decreasing treatment durations, and creating strategies to target at risk groups and screen for AHCV.

Original languageEnglish
Pages (from-to)599-610
Number of pages12
JournalExpert Review of Anti-Infective Therapy
Issue number8
StatePublished - 3 Aug 2018


  • Acute hepatitis C virus
  • HIV
  • direct-acting antiviral therapy
  • sofosbuvir


Dive into the research topics of 'Direct-acting antiviral treatment of acute hepatitis C virus infections'. Together they form a unique fingerprint.

Cite this